Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). (Q44293685)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). |
scientific article |
Statements
1 reference
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). (English)
1 reference
1 reference
Deenan Pillay
1 reference
Diana M Gibb
1 reference
A Sarah Walker
1 reference
Abdel G Babiker
1 reference
Alexandra Compagnucci
1 reference
Steve Kaye
1 reference
Mounir Ait-Khaled
1 reference
Anita De Rossi
1 reference
Clive Loveday
1 reference
David T Dunn
1 reference
1 December 2002
1 reference
1 reference
7
1 reference
4
1 reference
293-303
1 reference
Identifiers
1 reference